Citations

Clear

6729 citation(s) found for "Li, Mark".

On the Discorhabdins Leading to the Aleutianamine Ring System: A One‐Step in Situ Transformation Characterized Through Computational and Experimental Studies and Its Implications on Biosynthesis, Synthesis, and Pharmacology
Dickinson, Cody F. , Potluri, Abhay , Bland, Alison M. , Flipse, Samuel M., Hanna, George S., Wagner, Ryan T. , Ho, Thai H., Hoff, Gerald R., Stone, R. S., Tius, Marcus A. , Tantillo, Dean J., Hamann, Mark T., Dickinson, Cody F , Hanna, George S. , Robertson, Keith D. , Sprague, Daniel J. , Stone, Robert P., Tantillo, Dean J , Hamann, Mark T

Mayo Clinic

Angewandte Chemie | February 16, 2026 | Volume: 138 | Issue: 17 | Pages: No page available

10.1002/ange.7864883 Get It

ABSTRACT We disclose an efficient transformation of the relatively common pyrroloiminoquinone discorhabdin alkaloids from Alaskan Latrunculia spp. to the complex ring system of aleutianamine by an acid catalyzed process that mimics the proposed endogenous genesis from 3‐dihydrodienyl discorhabdin precursors. The azepine ring system is formed by a concerted 1,2‐alkyl shift of a proposed thiocarbenium‐iminium dication and this mechanism is supported by extensive density functional theory (DFT) analysis. Additional in vitro biological data further supports the aleutianamines as novel and highly potent inhibitors of multidrug resistant cancer lines exemplified further with cytotoxicity toward chemotherapy resistant chromophobe renal cell carcinoma (IC 50 = 130 nM). This report provides a key transformation that allows the incorporation of either synthetic or biosynthetic starting materials leading to the generation of the aleutianamine complex ring system in just a single step from the discorhabdin ring system.
On the Discorhabdins Leading to the Aleutianamine Ring System: A One‐Step in Situ Transformation Characterized Through Computational and Experimental Studies and Its Implications on Biosynthesis, Synthesis, and Pharmacology
Potluri, Abhay , Bland, Alison M. , Flipse, Samuel M., Hanna, George S., Wagner, Ryan T. , Ho, Thai H., Sprague, Daniel J. , Hoff, Gerald R., Stone, R. S., Tius, Marcus A. , Tantillo, Dean J., Hamann, Mark T., Dickinson, Cody F , Tantillo, Dean J , Hamann, Mark T , Dickinson, Cody F. , Hanna, George S. , Robertson, Keith D. , Stone, Robert P.

Mayo Clinic

Angewandte Chemie International Edition | February 16, 2026 | Volume: 65 | Issue: 17 | Pages: No page available

10.1002/anie.7864883 | PMID 41693117 Get It

ABSTRACT We disclose an efficient transformation of the relatively common pyrroloiminoquinone discorhabdin alkaloids from Alaskan Latrunculia spp. to the complex ring system of aleutianamine by an acid catalyzed process that mimics the proposed endogenous genesis from 3‐dihydrodienyl discorhabdin precursors. The azepine ring system is formed by a concerted 1,2‐alkyl shift of a proposed thiocarbenium‐iminium dication and this mechanism is supported by extensive density functional theory (DFT) analysis. Additional in vitro biological data further supports the aleutianamines as novel and highly potent inhibitors of multidrug resistant cancer lines exemplified further with cytotoxicity toward chemotherapy resistant chromophobe renal cell carcinoma (IC 50 = 130 nM). This report provides a key transformation that allows the incorporation of either synthetic or biosynthetic starting materials leading to the generation of the aleutianamine complex ring system in just a single step from the discorhabdin ring system.
International Multidisciplinary Consensus Report on Definitions, Diagnostic Criteria, and Management of Fatty Pancreas: A Joint Statement Endorsed by EPC, APA, EASD, EASL, ESGAR, ESGE, ESP, ESPCG, ESPEN, ESPGHAN, IAP, JPS, KPBA, LAPSG, and UEG
Marchegiani, Giovanni, Hegyi, Peter, Archibugi, Livia, Valente, Roberto, Capurso, Gabriele, Witt, Heiko, Bonovas, Stefanos , Maisonneuve, Patrick, Verbeke, Caroline S., Dominguez‐Muñoz, J. Enrique, Scheers, Isabelle, Czakó, László, Wagner, R, Rebours, Vinciane, Öhlund, Daniel, Gubergrits, N. B. , Engjom, Trond , Neeße, Albrecht , Apte, Minoti V. , Braren, Rickmer, Bunduc, Stefania, Ceyhan, Güralp Onur, Chouhan, Manil Dinesh, Couvelard, Anne, Iglesia, Daniel de la, Drewes, Asbjørn Mohr, Sarasqueta, A. Farina, Francque, Sven, Frøkjær, Jens Brøndum, Iglesias‐Garcia, Julio, Garg, Pramod, Gerst, Felicia, Gulbinas, Antanas, Gürcinar, Ibrahim Halil, Heni, Martin , Jonas, E G, Kitano, M., Krag, Aleksander, Laukkarinen, J., Lipp, Mónika, Loveček, M., Martignoni, Marc E., Masip, Etna , Matsumoto, Ryotaro , Mozhynа, T. L. , Nosáková, Lenka, Ockenga, Johann , Pandanaboyana, Sanjay, Panić, Nikola , Papachristou, Georgios, Pasqua, Analía V. , Pawlak, Katarzyna Monika, Regel, Ivonne , Regnér, Sara, Singh, Vijay Kumar , Smits, M., Sung, Min Je , Tacelli, Matteo, Teutsch, Brigitta, Udrescu, Mihaela, Wilschanski, Michael , Yavas, Aslihan, Zamboni, G., Löhr, J. Matthias, Singh, Vijay , Drewes, Asbjørn Mohr , Regnér, Sara , Krag, Aleksander , Marchegiani, Giovanni , Pawlak, Katarzyna M. , Marchegiani, Giovanni , Hegyi, Peter , Archibugi, Livia , Bonovas, Stefanos , Verbeke, Caroline S , de-Madaria, Enrique , Wagner, Robert , Rebours, Vinciane , Öhlund, Daniel , Neesse, Albrecht , Bezmarević, Mihailo , Bunduc, Stefania , Iglesia, Daniel de la , Drenth, Joost P H , Gürcinar, Ibrahim Halil , Jonas, Eduard , Kitano, Masayuki , Obmann, Verena , Pandanaboyana, Sanjay , Pasqua, Analia Verónica , Pawlak, Katarzyna M , Regnér, Sara , Seicean, Andrada , Sung, Min Je , Taylor, Roy , Singh, Vijay P , Krag, Aleksander , Vujasinović, Miroslav , Demir, İhsan Ekin , Hegyi, Péter , Valente, Roberto, Capurso, Gabriele , Piovani, Daniele , Rosendahl, Jonas , Maisonneuve, Patrick , Karçaaltıncaba, Muşturay , Domínguez‐Muñoz, J. Enrique , Scheers, Isabelle , Czakó, László , Idılman, Ilkay S. , Overbeek, Kasper A. , Braren, Rickmer , Chouhan, Manil Dinesh , Couvelard, Anne , Cros, Jerome F. , de‐Madaria, Enrique , Drenth, Joost P.H. , Fracasso, Pierluigi , Francque, Sven , Frøkjær, Jens Brøndum , Iglesias‐García, Julio , Garg, Pramod, Gulbinas, Antanas , Hyun, Jong Jin , Jonas, Eduard , Kiriukova, Mariia A. , Laukkarinen, Johanna , Loveček, Martin , Molven, Anders , Nosáková, Lenka , Obmann, Verena Carola , Papachristou, Georgios I. , Peláez‐Luna, Mario , Robinson, Stuart Michael , Smits, Mark M. , Tacelli, Matteo , Teutsch, Brigitta , Udrescu, Mihaela, Yavas, Aslihan , Zamboni, Giulia Angela, Löhr, J.-Matthias

Mayo Clinic

United European Gastroenterology Journal | February 14, 2026 | Volume: 14 | Issue: 1 | Pages: No page available

10.1002/ueg2.70185 | PMID 41689768 Get It

ABSTRACT This international, multidisciplinary consensus report represents the first effort to systematically define and characterize fatty pancreas. A key outcome of this endeavor was the recommendation to adopt “fatty pancreas” as the standardized and inclusive term to describe all forms of fat accumulation in the pancreas. This terminological consensus provides a critical foundation for unified reporting and clinical communication. Another major contribution of the report is the consensus on diagnostic imaging findings, which was based on radiological and endoscopic modalities. The proposed criteria aim to enhance consistency in clinical assessment and support the development of standardized research protocols. In addition to establishing terminology and diagnostic frameworks, the report also synthesizes current knowledge across a wide range of relevant domains. These include the etiology and epidemiology of fatty pancreas, as well as its associations with alcohol consumption, smoking, acute and chronic pancreatitis, pancreatic exocrine insufficiency, type 2 diabetes mellitus, and surgical outcomes. The potential links between fatty pancreas and neoplastic conditions such as intraductal papillary mucinous neoplasms and pancreatic cancer are also addressed, alongside the current understanding of its metabolic implications (beta‐cell function and glucose homeostasis) and treatment strategies. Throughout the consensus process, a consistent theme emerged: the limited availability of high‐quality, prospective clinical data. Therefore, many of the recommendations in this report are based on expert consensus rather than strong empirical evidence. As such, the statements require rigorous prospective validation before they can be adopted into routine clinical practice. This underscores a critical need for further research, particularly studies aimed at clarifying causal relationships, validating diagnostic tools, and determining the clinical relevance of fatty pancreas across diverse patient populations. This report serves as both a summary of our current understanding and a roadmap for future investigations, aiming to close existing knowledge gaps and guide evidence‐based clinical practice in this emerging field.
Poster Session II - A221 A SYSTEMATIC REVIEW OF DEFINITIONS AND DIAGNOSIS OF CROHN’S DISEASE COLONIC STRICTURES
Lu, C, Dhaliwal, R, Kellar, Amelia , Rowan, Catherine , St-Pierre, J, Suarez, K E, O’Brien, M, Rosentreter, R E, Gulhati, Vishrut, Baker, M E, Bruining, D, Fletcher, J, Gordon, I, Jairath, V, Feagan, B, Rieder, F, Lu, C, Dhaliwal, R, St-Pierre, Joelle, O’brien, M, Rosentreter, Ryan E., Baker, Mark E. , Bruining, David H. , Fletcher, Joel G. , Feagan, B G

Mayo Clinic

Journal of the Canadian Association of Gastroenterology | February 13, 2026 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1093/jcag/gwaf042.220 Get It

Abstract Background Colonic strictures in Crohn’s disease (CD) are an important, but understudied clinical problem. Cross-sectional imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and intestinal ultrasound (IUS) effectively assess the small bowel in CD allowing for the diagnosis of strictures. However, radiologic definitions of colonic strictures and their diagnostic accuracy have not been developed. Endoscopic definitions of colonic strictures are the most well-described. Aims We aimed to systematically review available data to summarize definitions, diagnosis and differentiation between inflammation and fibrosis of colonic strictures on endoscopy, CT, MR, and IUS Methods We conducted a systematic review following PRISMA guidelines using MEDLINE, Scopus, CINAHL, and CENTRAL databases from inception to Oct 6, 2024 to identify literature with diagnostic imaging that included patients with colonic CD strictures. To distinguish fibrosis from inflammation, only studies comparing endoscopy or imaging to a full thickness histologic gold standard were included. Two stage screening was completed in duplicate, and risk of bias was assessed using QUADAS-2 Results 46 studies were eligible for inclusion. Definitions for colonic strictures on CT, MR, and IUS are heterogeneous with combinations of bowel wall thickness, luminal narrowing, and pre-stenotic dilation with no clear cut offs. Endoscopic definitions commonly included lack of colonoscope passage through a narrowed lumen. The diagnostic accuracy of colonic strictures on imaging to detect inflammation and fibrosis against a gold standard of endoscopy or surgical resection is unclear as direct comparisons are few. Meta-analyses were not conducted due to methodological heterogeneity of grading fibrosis and statistical heterogeneity of sensitivity, specificity, and accuracy of colonic stricture diagnoses limited by pooling with small bowel strictures in the studies Conclusions This systematic review describes a lack of definitions for the diagnosis of CD colonic strictures particularly on diagnostic imaging, and the limitations with the current available data to differentiate inflammation from fibrosis. Although bowel wall thickening, luminal narrowing, and pre-stenotic dilation are recognized as hallmark features of small bowel strictures, their adaptation to the colon requires further assessment. Definitions for colonic strictures should likely include imaging combined with endoscopy. Future endeavors are required to develop a consensus to define and diagnose colonic strictures on these modalities Funding Agencies None
Salvage Focal Therapy vs Radical Prostatectomy for Localized Radiorecurrent Prostate Cancer
Light, Alexander, Peters, Max, Arya, Manit, Tanaka, Mariana Bertoncelli , Dudderidge, Tim , Emberton, Mark, Grey, Alistair , Hindley, Richard, Laniado, Marc, McCraken, Stuart, Moore, Caroline M., Nigam, Raj , Noureldin, Mohamed , Reddy, Deepika, Virdi, Jaspal, Ahmed, Mohamed, Albisinni, Simone, Cathcart, P. , Joniau, S., Karnes, Robert Jeffrey, Persad, Raj , Rajwa, Paweł, Sanchez-Salas, Rafael, Shariat, Shahrokh F., Smith, Joseph A., Tilki, Derya, Poel, H. G. van der, Calleris, Giorgio , Gontero, P., Marra, Giancarlo, Ahmed, Hashim U., Joniau, Steven , Emberton, Mark , Rajwa, Paweł , Moore, Caroline M. , Joniau, Steven , Rajwa, Pawel , Light, Alexander J. W., Peters, Max , Emara, Amr M. , Moore, Caroline , Orczyk, Clément , Reddy, Deepika , Albisinni, Simone , Karnes, R. Jeffrey , Shariat, Shahrokh F. , Tilki, Derya , Poel, HG van der, Marra, Giancarlo , Ahmed, Hashim U. , Shah, Taimur Tariq

Mayo Clinic

JAMA Oncology | February 12, 2026 | Volume: 12 | Issue: 4 | Pages: 364

10.1001/jamaoncol.2025.6448 | PMID 41678176 Get It

Importance Patients with recurrent prostate cancer after previous radiotherapy typically have poor survival. Those with recurrences prostate confined might be suitable for salvage focal therapy (sFT) or salvage radical prostatectomy (sRP). sFT may offer good cancer control with comparatively less toxic effects, but outcomes beyond 5 years have not been reported, and no study has compared sFT to sRP. Objective To compare cancer control and perioperative complications among patients after sFT vs sRP. Design, Setting, and Participants In this international, multicenter cohort study of matched comparison data, patients undergoing sFT were derived from the prospective UK HIFU (high-intensity focused ultrasound) Evaluation and Treatment and International Cryotherapy Evaluation registries (9 centers; 2006-2024) and the prospective UK Focal Recurrent Assessment and Salvage Treatment cohort study (6 centers; 2014-2018). Patients undergoing sRP were derived from an international retrospective registry (12 centers in 8 countries; 2000-2021). Patients with biopsy-confirmed, localized recurrent prostate cancer postradiotherapy, either external beam radiotherapy, brachytherapy, or both, were included. Data were analyzed from March to July 2025. Exposures sFT using HIFU or cryotherapy vs sRP. Main Outcomes and Measures The primary outcome was cancer-specific survival up to 10 years. Secondary outcomes were overall survival, any perioperative complications (Clavien-Dindo grades 1-5), and major perioperative complications (Clavien-Dindo grades 3-5). Comparisons were made on matched patients following 1:1 cardinality matching within individual multiply-imputed datasets. Matching variables used were radiotherapeutic treatment, years between primary and salvage treatments, European Association of Urology recurrence risk group, and presalvage age, prostate-specific antigen, prostate volume, grade group, T stage, and androgen-deprivation therapy use. Results A total of 923 patients were eligible for matching (419 undergoing sFT and 504 undergoing sRP). Of the patients undergoing sFT, 325 (77.6%) underwent HIFU and the remainder cryotherapy, with 241 (57.5%) treated with quadrant ablation. Of patients treated with sRP, 376 (74.6%) underwent open surgery and the remainder robot-assisted surgery. For sFT vs sRP, 10-year cancer-specific survival was 92% (95% CI, 86%-98%) vs 99% (95% CI, 97%-100%), with no statistically significant difference (restricted mean time lost, −0.09 years; 95% CI, −0.22 to 0.03 years; P = .15; subdistribution hazard ratio, 0.45; 95% CI, 0.05-4.00; P = .47). There was no statistically significant difference in 10-year overall survival (restricted mean survival time, −0.13 years; 95% CI, −0.86 to 0.60 years; P = .72). Undergoing sRP was associated with statistically significant higher odds of any complication (adjusted odds ratio, 24.20; 95% CI, 12.94-45.27; P < .001) and major complication (adjusted odds ratio, 9.31; 95% CI, 3.42-25.36; P < .001). Conclusions and Relevance In this cohort study, sFT and sRP were effective for treating localized radiorecurrent prostate cancer, while sFT was associated with fewer perioperative complications. sFT may provide a favorable therapeutic ratio for many patients with localized radiorecurrent prostate cancer.
Residual Stone Volume Predicts Health Care Consumption and Stone Events: Analysis of Two-Year Results of the ASPIRE Study
Matlaga, Brian R., Johnson, Brett, Page, Jay, Wolf, J. Stuart, Preminger, Glenn M. , Jones, Loren, Sobol, Ilya , Stern, Karen , Lipkin, Michael, Cuellar, David, Cobb, Kaitlan, Barsky, Robert, Medairos, Robert, Marguet, Charles G., Nimmagadda, Naren , Levin, Michael, Chi, Thomas, Stern, Karen L , Mueller, Thomas J. , Wolf, Jeanette, Jones, Loren, Lipkin, Michael E. , Cuellar, David, Barsky, Robert I, White, Mark, Chi, Thomas

Mayo Clinic

Journal of Endourology | February 12, 2026 | Volume: 40 | Issue: 3 | Pages: 328-334

10.1177/08927790261420565 | PMID 41674087 Get It

Purpose: The ASPiration to Improve Renal Calculi Removal Effectiveness study showed steerable ureteroscopic renal evacuation (SURE) with CVAC that significantly reduced residual stone volume at 30 days vs standard ureteroscopy (URS). This report presents 2-year health care consumption and stone events (SE) and their link to residual stone volume and other variables ( n = 101 at primary end point; n = 93 at 2 years). Materials and Methods: Logistic regression identified predictors of health care consumption events (HCEs), that is, emergency department visits, hospitalization, surgical retreatment, and SE across the study population. Incidence was compared between the treatment groups with Kaplan–Meier survival analysis. Results: At 2 years, residual stone volume was significantly associated with both HCEs and SE. For every 100 mm 3 increase in residual stone volume, the HCE risk increased by 50% to 54%, and the SE risk increased by 70%. Stone-free rate, the number of residual fragments (RFs), and RF total stone burden (based on diameter) were not predictors. Significantly fewer HCEs occurred in the SURE group (3 vs 20 events, p = 0.0004). Survival analysis confirmed this (4.3% vs 20%, log-rank p = 0.02), with a 73% risk reduction (hazard ratio 0.27, 95% Cl 0.09–0.80, p = 0.02). Fewer SE occurred in the SURE group, although not statistically significant. These subjects also had longer event-free survival. Conclusion: High-quality volumetric analysis supports evaluation of stone removal therapies, as residual stone volume predicts HCEs and SE. SURE significantly reduces the downstream incidence and risk of HCEs compared with standard URS.
Dynamic feedback control of oncogenic tyrosine kinase signaling in acute leukemia
Lee, Jae Woong , Sun, Ruifeng , Kume, Kohei , Robinson, Mark E. , Cheng, Zhangliang, Cosgun, Kadriye Nehir , Ma, Ning , Hurtz, Christian , Geng, Huimin , Luger, S. M., MR, Litzow, Paietta, E, Vaidehi, Nagarajan , Müschen, Markus, Luger, Selina M. , Geng, Huimin , Lee, Jaewoong , Luger, Selina M , Litzow, Mark R. , Chen, Jianjun , Vaidehi, Nagarajan , Müschen, Markus , Müschen, Markus

Mayo Clinic

Science Signaling | February 10, 2026 | Volume: 19 | Issue: 924 | Pages: No page available

10.1126/scisignal.adw5054 | PMID 41666265 Get It

CD25 is a subunit of the interleukin-2 (IL-2) receptor on T cells and natural killer (NK) cells. Acute leukemias with oncogenic tyrosine kinases often include CD25 + leukemia subpopulations, which portend poor clinical outcomes for patients; however, acute leukemia cells do not respond to IL-2. Here, we identified CD25 and its phosphorylation by protein kinase Cδ (PKCδ) as central elements of a feedback loop that stabilized fluctuations in oncogenic tyrosine kinase signaling in acute lymphoblastic and myeloid leukemia. Genetic ablation of CD25 in murine and patient-derived xenograft (PDX) models of acute leukemias reduced clonal fitness, colony formation, and leukemia-initiation capacity in serial transplant recipients. Oncogenic tyrosine kinase signaling in leukemia cells stimulated NF-κB–mediated CD25 expression, whereas PKCδ-mediated phosphorylation of CD25 suppressed oncogenic tyrosine kinase signaling through inhibitory phosphatases, such as PTPN6. Interactome analyses and mass spectrometry–based global phosphoproteomic analyses showed that CD25 deletion abolished the phosphatase activity of PTPN6, resulting in enhanced activation of tyrosine kinases and NF-κB. Four injections of a CD25 antibody-drug conjugate induced complete remission in mice transplanted with PDX refractory leukemia. These findings highlight the dependency of tyrosine kinase–driven leukemias on robust feedback control and the role of PKCδ and CD25 in assembling its components.
Redefining Upfront Resectable Pancreatic Ductal Adenocarcinoma: Should Vein Abutment Matter?
Tan, Po Hong, Thiels, Cornelius A., Poruk, Katherine E. , Miller, R., Hor, Hoe Yan , Tu, Melody Pi Yin , Huyser, Michelle R., Stucky, Chee-Chee, Wasif, Nabil , Bold, Richard J. , Smoot, R., Starlinger, Patrick P., Warner, Susanne G., Kendrick, M., Stauffer, John A., Truty, M., Fong, Zhi Ven, _, _, Poruk, Katherine, Miller, Richard Max, Thiels, Cornelius A. , Stucky, Chee‐Chee , Starlinger, Patrick , Warner, Susanne G. , Kendrick, Michael L. , Stauffer, John , Truty, Mark J. , Fong, Zhi Ven

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 9, 2026 | Volume: 24 | Issue: 2 | Pages: 27-33

10.6004/jnccn.2025.7097 | PMID 41671431 Get It

Background: Upfront resectable pancreatic ductal adenocarcinoma (PDAC) is defined by the NCCN as disease with ≤180° portomesenteric vein (PMV) abutment. However, the clinical significance of PMV abutment in this cohort remains unexplored, and we sought to investigate its impact. Methods: This multi-institutional study included patients who underwent pancreatoduodenectomy (PD) for upfront resectable PDAC from 2002 to 2023. Patients with PDAC with ≤180° PMV abutment were compared with those without. Overall survival (OS) was compared and stratified based on whether patients underwent upfront surgery or neoadjuvant therapy (NAT). Results: Among 1,446 patients included, 521 (36.0%) had PMV abutment. Median OS for patients with PMV abutment was 28.8 months compared with 31.2 months for those without ( P =.17). In a stratified analysis of patients who underwent upfront surgery, patients with PMV abutment had worse OS (19.2 vs 27.6 months; P <.05) and lower R0 resection rates (63.1% vs 87.2%; P <.05) compared with those without. However, in patients who underwent NAT, this difference in R0 resection rate was not observed (91.4% vs 94.0%, respectively; P =.27). Furthermore, there was no significant difference in median OS with NAT (42.5 vs 51.6 months, respectively; P =.48). Conclusions: In this largest cohort to date of patients with upfront resectable PDAC, PMV abutment was associated with worse OS compared with no PMV abutment when an upfront resection strategy was used. The use of NAT in patients with PMV abutment mitigated this survival difference with increased R0 resection rates. These findings suggest that patients with upfront resectable PDAC with PMV abutment benefit from a NAT approach for optimal survival outcomes, and that the current criteria guidelines need to be redefined.
Engineering the Future of Heart Failure Therapeutics: Integrating 3D Printing, Silicone Molding, and Translational Development for Implantable Cardiac Devices
Eagle, Carleigh , Desai, Aarti , Franklin, Michael J. , Pooley, Robert A. , Johnson, Elizabeth Oluwanifemi, Robinson, Shawn , Lopez, mark, Goswami, Rohan, Goswami, Rohan , Franklin, Michael, Pooley, Robert, Johnson, Elizabeth , Goswami, Rohan M , Desai, Aarti , Franklin, Michael, Johnson, Elizabeth

Mayo Clinic

Bioengineering | February 9, 2026 | Volume: 13 | Issue: 2 | Pages: 192

10.3390/bioengineering13020192 | PMID 41749732 Get It

Three-dimensional (3D) anatomic modeling derived from high-resolution medical imaging, such as computed tomography (CT) and magnetic resonance imaging (MRI), has been increasingly adopted in preclinical testing and device development. This white paper describes a cardiac-specific workflow that integrates 3D printing and silicone molding for support device development and procedural simulation. Patient-derived computed tomography angiography data were segmented using FDA-cleared medical modeling software to isolate the left ventricular anatomy and were further processed in computer-aided design (CAD) to ensure accurate physiological wall thickness and structural fidelity. Material jetting 3D printing was performed on a Stratasys J750 using material distributions designed to mimic the mechanical properties of myocardium, thereby approximating myocardial compliance. In parallel, stereolithography apparatus molds were designed from the left ventricle CAD model to cast transparent, pliable left ventricular models in Sorta-Clear™ 18 silicone. The 3D-printed models preserved intricate morphological detail and were suitable for mechanical manipulation and device deployment studies, whereas silicone models offered tunable mechanical properties, transparency for visualization, and durability for repeated use. Together, these complementary modalities provided rapid manufacturing capability and application-relevant physical representation. Case-specific parameters, strengths, and limitations of both models in enhancing patient care and device testing are highlighted, with relevance to heart failure applications. Current knowledge gaps, workflow and integration challenges, and future opportunities are identified, positioning this work as a reference framework for continued innovation in anatomic modeling. Within the collaborative framework of Mayo Clinic’s Anatomic Modeling Unit and Simulation Center, this integrated modeling workflow demonstrates the value of multidisciplinary collaboration between engineers and clinicians. Clinically, these patient-specific left ventricular models may enable pre-procedural device sizing and positioning and may support simulation of mechanical circulatory support (MCS) deployment while identifying possible anatomic constraints prior to intervention. This workflow has direct applicability in advanced heart failure patients undergoing MCS support, such as the Impella axillary MCS device or the durable LVAD, with potential to reduce procedural uncertainty while reducing complications and improving peri-procedural outcomes. Additionally, these models also serve as high-accuracy educational tools, enabling trainees and multidisciplinary care teams to visualize and possibly rehearse procedural steps while gaining hands-on experience in a risk-free environment.
Switching patients with PNH from pegcetacoplan to iptacopan: a case series
Sanikommu, Srinivasa Reddy , Maciejewski, J, Dingli, David, Dingli, David , Dingli, David , Orland, Mark D. , Gurnari, Carmelo

Mayo Clinic

Hematology | February 9, 2026 | Volume: 31 | Issue: 1 | Pages: No page available

10.1080/16078454.2026.2618403 | PMID 41657019 Get It